Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting

Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear requirement for a more effective, novel treatment option. Glofitamab is a CD20xCD3 T-cell-en...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chaoyu, Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999586/
https://www.ncbi.nlm.nih.gov/pubmed/36895020
http://dx.doi.org/10.1186/s13045-023-01420-w
_version_ 1784903688178892800
author Wang, Chaoyu
Liu, Yao
author_facet Wang, Chaoyu
Liu, Yao
author_sort Wang, Chaoyu
collection PubMed
description Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear requirement for a more effective, novel treatment option. Glofitamab is a CD20xCD3 T-cell-engaging, bispecific antibody capable of recruiting T cells to tumor cells. We have summarized several of the latest reports on glofitamab use in B cell lymphoma therapy from the 2022 ASH Annual Meeting (ASH2022).
format Online
Article
Text
id pubmed-9999586
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99995862023-03-11 Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting Wang, Chaoyu Liu, Yao J Hematol Oncol Correspondence Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear requirement for a more effective, novel treatment option. Glofitamab is a CD20xCD3 T-cell-engaging, bispecific antibody capable of recruiting T cells to tumor cells. We have summarized several of the latest reports on glofitamab use in B cell lymphoma therapy from the 2022 ASH Annual Meeting (ASH2022). BioMed Central 2023-03-10 /pmc/articles/PMC9999586/ /pubmed/36895020 http://dx.doi.org/10.1186/s13045-023-01420-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Wang, Chaoyu
Liu, Yao
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
title Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
title_full Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
title_fullStr Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
title_full_unstemmed Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
title_short Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
title_sort glofitamab therapy for diffuse large b cell lymphoma: latest updates from the 2022 ash annual meeting
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999586/
https://www.ncbi.nlm.nih.gov/pubmed/36895020
http://dx.doi.org/10.1186/s13045-023-01420-w
work_keys_str_mv AT wangchaoyu glofitamabtherapyfordiffuselargebcelllymphomalatestupdatesfromthe2022ashannualmeeting
AT liuyao glofitamabtherapyfordiffuselargebcelllymphomalatestupdatesfromthe2022ashannualmeeting

Ejemplares similares